CNS Pharmaceuticals (CNSP) Competitors $7.39 -0.13 (-1.73%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.46 +0.08 (+1.01%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. PRPH, NXTC, SNGX, TXMD, LGVN, HCWB, BFRG, IMCC, MRKR, and LPTXShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include ProPhase Labs (PRPH), NextCure (NXTC), Soligenix (SNGX), TherapeuticsMD (TXMD), Longeveron (LGVN), HCW Biologics (HCWB), Bullfrog AI (BFRG), IM Cannabis (IMCC), Marker Therapeutics (MRKR), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors ProPhase Labs NextCure Soligenix TherapeuticsMD Longeveron HCW Biologics Bullfrog AI IM Cannabis Marker Therapeutics Leap Therapeutics CNS Pharmaceuticals (NASDAQ:CNSP) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings. Does the media favor CNSP or PRPH? In the previous week, ProPhase Labs had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 7 mentions for ProPhase Labs and 6 mentions for CNS Pharmaceuticals. ProPhase Labs' average media sentiment score of 1.45 beat CNS Pharmaceuticals' score of 0.09 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CNS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral ProPhase Labs 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CNSP or PRPH? CNS Pharmaceuticals presently has a consensus target price of $20.00, suggesting a potential upside of 170.64%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe CNS Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, CNSP or PRPH? CNS Pharmaceuticals has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.78, meaning that its stock price is 178% less volatile than the S&P 500. Is CNSP or PRPH more profitable? CNS Pharmaceuticals' return on equity of -183.89% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets CNS PharmaceuticalsN/A -183.89% -139.37% ProPhase Labs N/A -262.42%-76.48% Which has higher valuation & earnings, CNSP or PRPH? CNS Pharmaceuticals has higher earnings, but lower revenue than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00ProPhase Labs$6.77M2.66-$53.36M-$1.26-0.34 Do insiders and institutionals have more ownership in CNSP or PRPH? 14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of ProPhase Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryCNS Pharmaceuticals beats ProPhase Labs on 8 of the 14 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.32M$3.20B$5.87B$10.14BDividend YieldN/A2.30%5.68%4.59%P/E Ratio0.0021.1774.5225.93Price / SalesN/A480.02549.78198.13Price / CashN/A46.6837.5660.44Price / Book0.119.6112.166.29Net Income-$14.86M-$53.29M$3.28B$270.77M7 Day Performance19.66%0.28%0.87%3.88%1 Month Performance8.84%5.73%4.96%4.88%1 Year Performance-91.69%10.52%60.74%26.01% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals1.7359 of 5 stars$7.39-1.7%$20.00+170.6%-91.7%$4.32MN/A0.005News CoverageAnalyst UpgradeShort Interest ↑PRPHProPhase Labs1.4727 of 5 stars$0.34-2.4%N/A-83.3%$14.05M$6.77M-0.27130News CoveragePositive NewsAnalyst UpgradeShort Interest ↓Gap DownNXTCNextCure4.7458 of 5 stars$5.03-1.9%$25.50+407.0%-68.0%$13.46MN/A-0.1990Positive NewsShort Interest ↓Gap DownSNGXSoligenix2.7408 of 5 stars$3.10+1.3%$6.00+93.5%-14.9%$13.28M$120K-0.8220Positive NewsShort Interest ↓TXMDTherapeuticsMD1.4717 of 5 stars$1.11-0.9%N/A-38.0%$12.85M$1.76M0.00420Positive NewsShort Interest ↓LGVNLongeveron3.1646 of 5 stars$0.83-0.2%$7.67+825.8%-61.0%$12.57M$2.39M-0.1320Positive NewsGap DownHCWBHCW Biologics2.0623 of 5 stars$5.72+0.7%$35.00+511.9%-75.5%$12.31M$2.57M-0.4140Short Interest ↑BFRGBullfrog AI1.1778 of 5 stars$1.21-1.6%N/A-45.6%$12.20M$60K-1.594IMCCIM Cannabis0.8543 of 5 stars$2.32-4.9%N/A-15.8%$12.17M$39.44M-4.30340Short Interest ↓Gap DownMRKRMarker Therapeutics3.6592 of 5 stars$0.93+3.3%$13.17+1,322.3%-66.0%$11.98M$6.59M-0.6860Short Interest ↑Gap UpLPTXLeap Therapeutics2.723 of 5 stars$0.29-2.3%$3.38+1,070.2%-89.4%$11.95MN/A-0.1840Positive NewsGap Down Related Companies and Tools Related Companies PRPH Competitors NXTC Competitors SNGX Competitors TXMD Competitors LGVN Competitors HCWB Competitors BFRG Competitors IMCC Competitors MRKR Competitors LPTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
